

Re Tenofovir

I write on behalf of the College of Pathologists and the UK Clinical Virology Network. This is a safe drug that is well known to virologists and those who treat HIV as well as, increasingly, those who treat HBV. It is clear it is already becoming frontline because of its efficacy and perceived low level of resistance. Your recommendations endorse this view. We have no substantive problems with it. I have insufficient knowledge of economic models to comment on those aspects.

I would have thought NICE should not become embroiled in discussions regarding single use tenofovir or its use in combination. This area is at an early stage (and confused, with little evidence either way) for all drugs used in HBV therapy and whatever NICE's recommendations, it will be used according to upcoming clinical trial data as hepatologists are a large international community and mostly do what everyone else is doing ie whatever has been shown in trials to work. Just because combination therapy is used in HIV does not mean it should be used in HBV.

I hoe this helps

[REDACTED]